Home
Search Center
Journal List
CMA
Contact US
|
Chinese
You Position:
Home
> Paper
Lysosomal-associated protein transmembrane-4 beta: a novel potential biomarker for cancer therapy with multiple functions
( views:0, downloads:0 )
Author:
No author available
Journal Title:
Chinese Medical Journal
Issue:
1
DOI:
10.1097/CM9.0000000000001021
Key Word:
No keyword available
Abstract: No abstract available
Reference
[1].
Investigation of Polyamine Metabolism and Homeostasis in Pancreatic Cancers.
[J].2017,5(4).
[2]Matthew Locke,Essam Ghazaly,Marta O. Freitas,etc.
Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1
[J].2016,(6).
[3]Castello G,Ottaiano A,Prestayko AW,etc.
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.
[J].2005,23(30).
[4]Korde Choudhari Sheetal,Chaudhary Minal,Bagde Sachin,etc.
Nitric oxide and cancer: a review
[J].2013,11(1).
[5]Kaira,K.,Sunose,Y.,Arakawa,K.,etc.
Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer
[J].2012,107(4).
[6]Deborah A. Altomare,Sarah B. Gitto,Veethika Pandey,etc.
Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer
[J].2018,15(2).
[7]Xazmin H,Lowman,Eric A,Hanse,Ying,Yang,etc.
p53 Promotes Cancer Cell Adaptation to Glutamine Deprivation by Upregulating Slc7a3 to Increase Arginine Uptake.
[J].2019,26(11).
[8]Feun,L.G.,Marini,A.,Walker,G.,etc.
Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
[J].2012,106(9).
[9]Burki, Talha Khan.
Arginine deprivation for ASS1-deficient mesothelioma
[J].2016,17(10).
[10].
Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer.
[J].2017.
[11]Cheng, P. N.,Leung, Y. C.,Lo, W. H.,etc.
Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular c
[J].2005,224(1).
[12]Bowles TL,Kim R,Galante J,etc.
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
[J].2008,123(8).
[13]О А, Samoilenko,O A, Milinevska,O V, Karnaushenko,etc.
Effect of polyamine metabolism inhibitors on Lewis lung carcinoma growth and metastasis.
[J].2015,37.
[14]P K, Lala,C, Chakraborty.
Role of nitric oxide in carcinogenesis and tumour progression.
[J].2001,2(3).
[15]Alistar, Angela,Morris, Bonny B.,Desnoyer, Rodwige,etc.
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
[J].2017,18(6).
[16].
ADI-PEG 20 Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma.
[J].2018,(Spec).
[17]Chantranupong, Lynne,Scaria, Sonia M.,Saxton, Robert A.,etc.
The CASTOR Proteins Are Arginine Sensors for the mTORC1 Pathway
[J].2016,165(1).
[18]Joseph G. Vockley,Christopher P. Jenkinson,Hridayabiranjan Shukla,etc.
Cloning and Characterization of the Human Type II Arginase Gene
[J].1996,38(2).
[19]Wyant, Gregory A.,Abu-Remaileh, Monther,Wolfson, Rachel L.,etc.
mTORC1 Activator SLC38A9 Is Required to Efflux Essential Amino Acids from Lysosomes and Use Protein as a Nutrient
[J].2017,171(3).
[20].
Tumour maintenance is mediated by eNOS
[J].2008,452(TN.7187).
[21]Kasten,J.,Hu,C.,Bhargava,R.,etc.
Lethal phenotype in conditional late-onset arginase 1 deficiency in the mouse
[J].2013,110(3).
[22]Siegel Rebecca L.,Miller Kimberly D.,Jemal Ahmedin.
Cancer statistics, 2020
[J].2020,70(1).
[23]Lampson,B.L.,Kendall,S.D.,Ancrile,B.B.,etc.
Targeting eNOS in pancreatic cancer
[J].2012,72(17).
[24].
Screening for pancreatic cancer: Why, how, and who?
[J].2013,257(1).
[25]A K, Nussler,S, Gansauge,F, Gansauge,etc.
Overexpression of endothelium-derived nitric oxide synthase isoform 3 in the vasculature of human pancreatic tumor biopsies.
[J].1998,383.
[26]Ding, Guiling,Chen, Ying,Jin, Gang,etc.
CD13(hi) Neutrophil-like myeloid-derived suppressor cells exert immune suppression through Arginase 1 expression in pancreatic ductal adenocarcinoma
[J].2017,6(2).
[27]Karakhanova, Svetlana,Link, Julia,Heinrich, Moritz,etc.
Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells
[J].2015,4(4).
[28]Claudia P, Hernandez,Kevin, Morrow,Lluis A, Lopez-Barcons,etc.
Pegylated arginase I: a potential therapeutic approach in T-ALL.
[J].2010,115.
[29]Khalil Nathalie,Abi-Habib Ralph J..
[HuArgI (co)-PEG5000]-induced arginine deprivation leads to autophagy dependent cell death in pancreatic cancer cells
[J].2019,38(5).
[30]Singh, Pankaj K.,Deorukhkar, Amit A.,Venkatesulu, Bhanu P.,etc.
Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation
[J].2019,18(12).
[31]Commisso Cosimo,Davidson Shawn M.,Soydaner-Azeloglu Rengin G.,etc.
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
[J].2013,497(7451).
[32]Peter W, Szlosarek,Jeremy P, Steele,Luke, Nolan,etc.
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
[J].2017,3(1).
[33]Tamara, Zaytouni,Pei-Yun, Tsai,Daniel S, Hitchcock,etc.
Critical role for arginase 2 in obesity-associated pancreatic cancer.
[J].2017,8(1).
[34]Albino V,Piccirillo M,Palaia R,etc.
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.
[J].2010,28(13).
[35]Kuldeep S, Attri,Kamiya, Mehla,Pankaj K, Singh.
Evaluation of Macrophage Polarization in Pancreatic Cancer Microenvironment Under Hypoxia.
[J].2018,1742(Spec ).
[36]Buga GM,Fukuto JM,Bauer PM,etc.
NG-hydroxy-L-arginine and nitric oxide inhibit Caco-2 tumor cell proliferation by distinct mechanisms.
[J].1998,275(4 Pt.2).
[37]Sze-Kwan,Lam,Sheng,Yan,Shi,Xu,etc.
Endogenous arginase 2 as a potential biomarker for PEGylated arginase 1 treatment in xenograft models of squamous cell lung carcinoma.
[J].2019,8(3).
[38]Mossmann, Dirk,Park, Sujin,Hall, Michael N..
mTOR signalling and cellular metabolism are mutual determinants in cancer
[J].2018,18(12).
[39]Robert D,Leone,Liang,Zhao,Judson M,Englert,etc.
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion.
[J].2019,366(6468).
[40]Wang, Jian,Yang, Shouhui,He, Peijun,etc.
Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer
[J].2016,22(24).
[41]Benjamin Bonavida,Hermes Garban.
Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics
[J].2015,6.
[42]Wang, Jen Chin,Kundra, Ajay,Andrei, Mirela,etc.
Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm
[J].2016,43.
[43]Jeff Charles Kremer,Bethany Cheree Prudner,Sara Elaine Stubbs Lange,etc.
Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers
[J].2017,18(4).
[44]Long,Y.,Aiba,I.,Kuo,M.T.,etc.
Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells
[J].2012,72(10).
[45]DeSelm, Carl J.,Tano, Zachary E.,Varghese, Anna M.,etc.
CAR T-cell therapy for pancreatic cancer
[J].2017,116(1).
[46]Kendzicky,A.,Samal,K.,Gerner,E.,etc.
AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport
[J].2013,133(6).
[47]Mussai Francis,Wheat Rachel,Sarrou Evgenia,etc.
Targeting the arginine metabolic brake enhances immunotherapy for leukaemia
[J].2019,145(8).
[48]Rebecca A. Redman,Paula Raffin Pohlmann,Michael R. Kurman,etc.
A phase I, dose-escalation, multi-center study of PFK-158 in patients with advanced solid malignancies explores a first-in-man inhbibitor of glycolysis.
[J].2019,33(15_suppl).
[49]Diers, Anne R.,Chang, Ching-Fang,Hogg, Neil.
Cancer cell metabolism and the modulating effects of nitric oxide
[J].2015,79.
[50]Prudner, Bethany C.,Rathore, Richa,Robinson, Anthony M.,etc.
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors
[J].2019,25(16).
[51]Sharma, Padmanee,Allison, James P..
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
[J].2015,161(2).
[52]Morris,Sidney M..
Arginine Metabolism: Boundaries of Our Knowledge
[J].2007,137(6).
[53]Suchithra Menon,Christian C. Dibble,George Talbott,etc.
Spatial Control of the TSC Complex Integrates Insulin and Nutrient Regulation of mTORC1 at the Lysosome
[J].2014,156(4).
[54]Fujita,M.,Imadome,K.,Endo,S.,etc.
Nitric oxide increases the invasion of pancreatic cancer cells via activation of the PI3K-AKT and RhoA pathways after carbon ion irradiation
[J].2014,588(17).
[55]Jahani, Mozhgan,Noroznezhad, Fatemeh,Mansouri, Kamran.
Arginine: Challenges and opportunities of this two-faced molecule in cancer therapy
[J].2018,102.
[56]S M, Vickers,L A, MacMillan-Crow,M, Green,etc.
Association of increased immunostaining for inducible nitric oxide synthase and nitrotyrosine with fibroblast growth factor transformation in pancreatic cancer.
[J].1999,134.
[57]Castello G,Bomalaski JS,Clark MA,etc.
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies.
[J].2004,22(10).
[58]Kamphorst, Jurre J.,Nofal, Michel,Commisso, Cosimo,etc.
Human Pancreatic Cancer Tumors Are Nutrient Poor and Tumor Cells Actively Scavenge Extracellular Protein
[J].2015,75(3).
[59]E Ramsay, Camp,Anthony, Yang,Wenbiao, Liu,etc.
Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
[J].2006,12.
[60]Long,Y.,Tsai,W.-B.,Wangpaichitr,M.,etc.
Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction
[J].2013,12(11).
[61]Zou, Songyun,Wang, Xiangmei,Liu, Po,etc.
Arginine metabolism and deprivation in cancer therapy
[J].2019,(118).
[62]Maeve A. Lowery,Kenneth H. Yu,David Paul Kelsen,etc.
A phase 1/1B trial of ADI‐PEG 20 plus nab‐paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma
[J].2017,123(23).
[63]Altaf, Mohammed,Naveena B, Janakiram,Venkateshwar, Madka,etc.
Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.
[J].2014,7.
[64]Liu Jiangbo,Ma Jiguang,Wu Zheng,etc.
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling
[J].2014,14(1).
[65]Brahmer,J.R.,Tykodi,S.S.,Chow,L.Q.M.,etc.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
[J].2012,366(26).
[66]De Santo Carmela,Cheng Paul,Beggs Andrew,etc.
Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma
[J].2018,11(1).
[67]Jian, Wang,Peijun, He,Matthias, Gaida,etc.
Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer.
[J].2016,(33).
[68]Dreyer, Stephan B.,Chang, David K.,Bailey, Peter,etc.
Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
[J].2017,23(7).
[69]Nevala-Plagemann, Christopher,Hidalgo, Manuel,Garrido-Laguna, Ignacio.
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
[J].2020,17(2).
[70]Levy C,Rosenberg SA,Turner K,etc.
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.
[J].2010,33(8).
[71]Yao, Wantong,Rose, Johnathon L.,Wang, Wei,etc.
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer
[J].2019,568(Apr.18 TN.7752).
[72]Coothankandaswamy, V.,Cao, S.,Xu, Y.,etc.
Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer
[J].2016,173(23).
[73]R, Singh,S, Pervin,A, Karimi,etc.
Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells.
[J].2000,60.
[74]Bachrach U,Tabib A,Wang YC.
Polyamines: New cues in cellular signal transduction
[J].2001,16(3).
WanfangData CO.,Ltd All Rights Reserved
About WanfangData
|
Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:
yiyao@wanfangdata.com.cn